Mersana Therapeutics Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Cambridge, Massachusetts and currently employs 102 full-time employees. The company went IPO on 2017-06-28. Mersana Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is focused on the development of antibody-drug conjugates (ADCs), which offer a clinically meaningful benefit for cancer patients with significant unmet needs. The company has developed two proprietary and differentiated ADC platforms: Dolasynthen and Immunosynthen. Dolasynthen is a cytotoxic ADC platform that is designed to generate site-specific, homogeneous ADCs. Immunosynthen is its proprietary stimulator of interferon genes (STING)-agonist platform that is designed to generate systemically administered ADCs that locally activate STING signaling in both antigen-expressing tumor cells and in tumor-resident immune cells. The firm's pipeline includes Emi-Le (emiltatug ledadotin; XMT-1660), a Dolasynthen ADC targeting B7-H4, and XMT-2056, an Immunosynthen ADC targeting a novel epitope of human epidermal growth factor receptor 2 (HER2).
Follow-Up Questions
Mersana Therapeutics Inc 'in CEO'su kimdir?
Dr. Martin Huber 2020 'den beri şirketle birlikte olan Mersana Therapeutics Inc 'in President 'ıdır.
MRSN hissesinin fiyat performansı nasıl?
MRSN 'in mevcut fiyatı $7.35 'dir, son işlem günde 0% decreased etti.
Mersana Therapeutics Inc için ana iş temaları veya sektörler nelerdir?
Mersana Therapeutics Inc Biotechnology endüstrisine ait ve sektör Health Care 'dir
Wall Street analistlerine göre, 9 analist Mersana Therapeutics Inc için analist derecelendirmeleri gerçekleştirdi, bunlar 7 güçlü al, 6 al, 2 tut, 0 sat ve 7 güçlü sat içermektedir
